Intestinal Research10.5217/ir.2020.00117202220172-77Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort studyVitaliy Y. Poylin, Jose Cataneo Serrato, Jonathan Pastrana Del Valle, Joseph D. Feuerstein,,
Journal of Crohn's and Colitis10.1093/ecco-jcc/jjab232.423202216Supplement_1i326-i326P296 vedolizumab Does Not Increase Risk of Clostridium Difficile Infection in Patients with Inflammatory Bowel Disease Using vedolizumab: a Retrospective Cohort StudyA Alshahrani,
Gastroenterology10.1016/s0016-5085(18)31630-520181546S-402Sa1806 - Vedoizumab Does not Increase Perioperative Surgical Complications in Patients with Inflammatory Bowel DiseaseVitaliy Y. Poylin, Jose Cataneo, Jonathan Pastrana, Joseph D. Feuerstein,
Inflammatory Bowel Diseases10.1093/ibd/izy146201824122657-2657Corrigendum to Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study
Intestinal Research10.5217/ir.2021.0017020222011-2Which biologic agents increase perioperative complications in patients with inflammatory bowel disease?Jihye Park,,
The Surgeon10.1016/j.surge.2020.09.0012021195e153-e167Does perioperative biological therapy increase 30-day post-operative complication rates in inflammatory bowel disease patients undergoing intra-abdominal surgery? A systematic reviewLaura Wilhelmina Byrne, Damian McKay,
Journal of Crohn's and Colitis10.1093/ecco-jcc/jjac190.1015202317Supplement_1i1003-i1004P885 Does long term corticosteroid use increase the risk of femur fracture in Inflammatory Bowel Disease patients? : A nationwide population-based cohort studyB Kim, J Sung Hoon, L Jiyoung,
Journal of Crohn's and Colitis10.1093/ecco-jcc/jjab073.088202115Supplement_1S085-S085DOP49 Effectiveness and safety of vedolizumab in a matched cohort of elderly and young Inflammatory Bowel Disease patients - LIVE Study-GroupD Pugliese, G Privitera, A Armuzzi,
Gastroenterology10.1016/s0016-5085(20)32391-x20201586S-680Su1864 VEDOLIZUMAB IS SAFE IN VETERAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE OVER AGE 65: RETROSPECTIVE COHORTKenneth Leung, Christian S. Jackson, Muhammad B. Hammami,
Gastroenterology10.1016/s0016-5085(21)01545-620211606S-346Fr524 EFFICACY OF VEDOLIZUMAB IN A NATIONWIDE COHORT OF ELDERLY INFLAMMATORY BOWEL DISEASE PATIENTSAlexandra Weiss, Chinmay Trivedi, Tyler Pernes, Manthankumar Patel, Nabeel H. Khan,